STOCK TITAN

Dynavax Technolo - DVAX STOCK NEWS

Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.

Dynavax Technologies Corporation (DVAX) delivers innovative vaccine solutions through cutting-edge immunological research and strategic commercialization. This news hub provides investors and healthcare professionals with essential updates on the biopharmaceutical leader's clinical developments, regulatory milestones, and market activities.

Track all critical DVAX updates in one place: Access press releases covering vaccine trial progress, FDA decisions, financial results, and partnership announcements. Our curated feed includes updates on HEPLISAV-B commercialization, CpG 1018 adjuvant applications, and pipeline developments across infectious disease and cancer immunotherapy programs.

Key coverage areas: Regulatory submissions for new vaccine candidates, quarterly earnings reports, manufacturing expansions, and scientific presentations. Content is rigorously verified to ensure accuracy for both professional investors and those monitoring public health advancements.

Bookmark this page for continuous access to Dynavax's official communications and analysis of strategic initiatives shaping the future of preventive healthcare. Check regularly for developments impacting vaccine accessibility and immunological innovation.

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) has secured a $22 million agreement with the U.S. Department of Defense to develop a recombinant plague vaccine using its CpG 1018 adjuvant over two and a half years. This collaboration includes a planned Phase 2 clinical trial, expected to commence in 2022, to assess the vaccine's immunogenicity, safety, and tolerability for adults aged 18 to 55 years. The initiative aims to enhance vaccine effectiveness and could lead to future commercial agreements with the U.S. government.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
-
Rhea-AI Summary

On October 1, 2021, Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of 40,000 nonstatutory stock options to a newly-hired employee as part of their inducement for joining the company. The options are priced at $16.84 per share, equal to the stock's closing price on the grant date. They have a seven-year term, vesting over three years, with one-third vesting after one year and the remainder vesting monthly. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
-
Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) will participate in several upcoming investor conferences, showcasing its commitment to vaccine development. Key presentations include the 2021 Cantor Virtual Global Healthcare Conference on September 30 at 12:00 p.m. E.T., the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on October 5 at 12:00 p.m. E.T., and the H.C. Wainwright 2nd Hepatitis B Virus Virtual Conference on October 13 at 12:00 p.m. E.T.. All events will be available via live webcast on their website's 'Events & Presentations' page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences
Rhea-AI Summary

On September 22, 2021, Dynavax Technologies (Nasdaq: DVAX) announced positive results from Clover Biopharmaceuticals' Phase 2/3 SPECTRA trial for their COVID-19 vaccine candidate, SCB-2019, adjuvanted with Dynavax's CpG 1018. The trial, involving over 30,000 participants, demonstrated 100% efficacy against severe COVID-19 and 84% against moderate-to-severe cases, achieving a 79% efficacy against the Delta variant. The vaccine showed a favorable safety profile, with adverse events balanced between vaccine and placebo groups. Clover plans to seek regulatory approvals in Q4 2021, potentially launching the vaccine by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.45%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX) announced that Valneva SE received a termination notice from the UK government regarding its COVID-19 vaccine supply agreement for VLA2001. Despite this, Valneva plans to continue clinical trials for VLA2001, with results expected in Q4 2021. Dynavax reiterated a potential revenue opportunity of $300-$400 million for its CpG 1018 adjuvant in 2021, contingent upon ongoing partnerships. There are concerns regarding the impact on Dynavax if Valneva cancels any purchase orders for CpG 1018, but no cancellations have occurred yet.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.01%
Tags
covid-19
-
Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) announces that CEO Ryan Spencer will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021.

The on-demand presentation will be accessible starting September 13, 2021, at 7:00 a.m. E.T. via the Company's Investors section. Dynavax focuses on the development and commercialization of vaccines, including its first product, HEPLISAV-B®, for Hepatitis B prevention.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.34%
Tags
conferences
Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) announced the granting of nonstatutory stock options for 224,000 shares to 8 new employees as an inducement for their employment. The options, priced at $19.00 per share, match the closing stock price on the grant date, September 1, 2021. The options vest over three years, with one-third vesting on the first anniversary and the remainder vesting in monthly increments. This grant complies with Nasdaq Listing Rule 5635(c)(4) and follows the company's 2021 Inducement Award Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
-
Rhea-AI Summary

Medigen Vaccine Biologics Corporation (MVC) and Dynavax Technologies Corporation (Nasdaq: DVAX) announced the rollout of MVC-COV1901, a COVID-19 vaccine, with an initial distribution to approximately 600,000 people in Taiwan. MVC recently received emergency use authorization from the Taiwan FDA for its two-dose vaccine, which utilizes Dynavax's CpG 1018 adjuvant. The vaccine showed promising safety and efficacy in clinical trials. MVC's CEO highlighted the importance of serving Taiwan during the pandemic, while Dynavax's CEO expressed hopes for further approvals of vaccines using their adjuvant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.37%
Tags
covid-19
-
Rhea-AI Summary

Dynavax Technologies (DVAX) reported Q2 2021 financial results showing significant growth. Total revenue reached $52.8 million, up from $2.7 million in Q2 2020. HEPLISAV-B net revenue was a record $13.7 million, while CpG 1018 contributed $39 million. The company announced a commercial supply agreement with Biological E for its COVID-19 vaccine candidate. Dynavax also increased its cash reserves to $345.8 million. The CDC is set to vote on a universal hepatitis B recommendation in October 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX) announced on August 3, 2021, the granting of stock options to purchase 438,000 shares to 44 new employees. The options, granted on August 2, 2021, have an exercise price of $9.45 per share, aligning with the closing stock price on that date. Each option has a 7-year term and vests over three years, with one-third vesting after one year. This action complies with Nasdaq Listing Rule 5635(c)(4) aimed at incentivizing new hires.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
Dynavax Technolo

Nasdaq:DVAX

DVAX Rankings

DVAX Stock Data

1.42B
121.70M
0.48%
107.55%
15.26%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
EMERYVILLE